Pharmacological approaches for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosis (Q35012421)

5 August 2017

1 reference

title

Pharmacological approaches for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosis (English)

1 reference

5 August 2017

0 references

Michael W Konstan

1

1 reference

5 August 2017

Pamela B Davis

series ordinal

2

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

Advanced Drug Delivery Reviews

5 August 2017

published in

1 reference

5 August 2017

volume

54

1 reference

5 August 2017

issue

11

1 reference

5 August 2017

page(s)

1409-1423

1 reference

Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis.

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Effect of high-dose ibuprofen in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

The use of anti-inflammatory medications in cystic fibrosis: trends and physician attitudes

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

The lung in cystic fibrosis. A quantitative study including prevalence of pathologic findings among different age groups

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Current understanding of the inflammatory process in cystic fibrosis: Onset and etiology

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Altered respiratory epithelial cell cytokine production in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Proinflammatory cytokine responses to P. aeruginosa infection in human airway epithelial cell lines

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Exaggerated activation of nuclear factor-kappaB and altered IkappaB-beta processing in cystic fibrosis bronchial epithelial cells

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

1 reference

7 January 2021

Diverse Pseudomonas aeruginosa gene products stimulate respiratory epithelial cells to produce interleukin-8

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Activation of NF-kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Activation of NF-kappaB in airway epithelial cells is dependent on CFTR trafficking and Cl- channel function

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Reduced upper airway nitric oxide in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Decreased concentration of exhaled nitric oxide (NO) in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Nasal and exhaled nitric oxide is reduced in adult patients with cystic fibrosis and does not correlate with cystic fibrosis genotype

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Protease-antiprotease imbalance in the lungs of children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Neutrophil elastase and cathepsin G stimulate secretion from cultured bovine airway gland serous cells

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Neutrophil elastase cleaves C3bi on opsonized pseudomonas as well as CR1 on neutrophils to create a functionally important opsonin receptor mismatch

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Complement receptor expression on neutrophils at an inflammatory site, the Pseudomonas-infected lung in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Beclomethasone diproprionate reduced airway inflammation without adrenal suppression in young children with cystic fibrosis: a pilot study

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

The effects of the inhaled corticosteroid budesonide on lung function and bronchial hyperresponsiveness in adult patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Pilot study to assess the effect of inhaled corticosteroids on lung function in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Controlled Trial of Inhaled Budesonide in Patients with Cystic Fibrosis and Chronic BronchopulmonaryPseudomonas aeruginosaInfection

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Patterns of medical practice in cystic fibrosis: part II. Use of therapies. Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Piroxicam treatment protects mice from lethal pulmonary challenge with Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. Implications for antiinflammatory therapy in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Inhibition of NF-kappaB and AP-1 activation by R- and S-flurbiprofen

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Non-steroidal anti-inflammatory drugs inhibit the expression of cytokines and induce HSP70 in human monocytes

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Prophylaxis and treatment of non-steroidal anti-inflammatory drug-induced upper gastrointestinal side-effects

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Anti-TNF therapy for rheumatoid arthritis and other inflammatory diseases

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Viral pneumonia as a serious complication of etanercept therapy

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

In vivo suppression of NF-kappa B and preservation of I kappa B alpha by interleukin-10 and interleukin-13

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

IL-10 attenuates excessive inflammation in chronic Pseudomonas infection in mice

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Inducible nitric oxide synthase expression is reduced in cystic fibrosis murine and human airway epithelial cells

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Cystic fibrosis transmembrane conductance regulator-dependent regulation of epithelial inducible nitric oxide synthase expression

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

In vivo alterations of IFN regulatory factor-1 and PIAS1 protein levels in cystic fibrosis epithelium

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Nonsteroidal therapy for idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

IDENTIFICATION OF LEUKOTRIENES D AND B IN SPUTUM FROM CYSTIC FIBROSIS PATIENTS

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Leukotrienes in the sputum and urine of cystic fibrosis children

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Leukotriene B4 markedly elevated in the epithelial lining fluid of patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Neutrophil accumulation in the lung in alpha 1-antitrypsin deficiency. Spontaneous release of leukotriene B4 by alveolar macrophages

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Current treatment of asthma--focus on leukotrienes

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Oral absorption of omega-3 fatty acids in patients with cystic fibrosis who have pancreatic insufficiency and in healthy control subjects

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Roxithromycin, clarithromycin, and azithromycin attenuate the injurious effects of bioactive phospholipids on human respiratory epithelium in vitro

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Interleukin-8 gene repression by clarithromycin is mediated by the activator protein-1 binding site in human bronchial epithelial cells

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial.

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

DNase I Acutely Increases Cystic Fibrosis Sputum Elastase Activity and its Potential to Induce Lung Hemorrhage in Mice

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

The effects of recombinant human DNase on neutrophil elastase activity and interleukin-8 levels in the sputum of patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

CpG oligodeoxynucleotides can reverse Th2-associated allergic airway responses and alter the B7.1/B7.2 expression in a murine model of asthma

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Antioxidant imbalance in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Hydrogen peroxide and nitric oxide in exhaled air of children with cystic fibrosis during antibiotic treatment

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Pulmonary oxidative stress response in young children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Systemic deficiency of glutathione in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Glutathione aerosol suppresses lung epithelial surface inflammatory cell-derived oxidants in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

The discovery and biologic properties of cephalosporin-based inhibitors of PMN elastase

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Aerosol α1 -antitrypsin treatment for cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Recombinant human Monocyte/Neutrophil elastase inhibitor protects rat lungs against injury from cystic fibrosis airway secretions

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

In vitro transport of active alpha(1)-antitrypsin to the apical surface of epithelia by targeting the polymeric immunoglobulin receptor.

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

Transport of bifunctional proteins across respiratory epithelial cells via the polymeric immunoglobulin receptor

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(02)00146-1

7 January 2021

10.1016/S0169-409X(02)00146-1

Identifiers

DOI

1 reference

5 August 2017

1 reference